BJ9 Stock Chart & Stats
€3.06
€0.00(0.00%)
At close: 4:00 PM EDT
€3.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.06 - €3.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€369.75M
Enterprise Value€341.96
Total Cash (Recent Filing)€184.76M
Total Debt (Recent Filing)€876.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Sep 30, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding34,354,336
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.73Price Target Upside348.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.87
Revenue Forecast (FY)€23.99M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low debt relative to equity gives the company durable financial flexibility uncommon in early-stage biotech. This reduces near-term refinancing risk, supports sustained R&D spending through internal resources and asset liquidation options, and lengthens runway versus highly levered peers.
Proprietary DdRNAi PlatformA proprietary gene-silencing platform represents a structural competitive advantage: it can spawn multiple candidate programs, enable long-duration therapeutic effects, and attract partnerships or licensing. Platform ownership supports scalable long-term value creation if clinical validation succeeds.
Sizable Reported AssetsApproximately $187M of assets provides a tangible cushion and runway to fund clinical and preclinical work without immediate dilution. Combined with low leverage, sizeable assets support multi-quarter program advancement and strategic optionality for licensing or collaboration talks.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$20M TTM indicates the company must rely on external financing to continue operations. Over months this erodes runway, increases dilution risk, and can constrain program prioritization if capital markets tighten or partner deals lag.
Minimal Commercial Revenue Vs Large LossesWith essentially no recurring product revenue and nearly $49M net loss TTM, the business remains pre-commercial and heavily cost-driven. Lack of revenue undermines self-funding, delays break-even potential, and magnifies the impact of any development setbacks on long-term viability.
Equity Being Consumed (negative ROE)A TTM ROE near -39% signals persistent erosion of shareholder capital from operating deficits. Over a multi-month horizon this reflects that R&D spend is not yet converting to value, heightening pressure to secure funding and potentially prompting reprioritization or dilution that affects long-term investor returns.
Benitec Biopharma News
BJ9 FAQ
What was Benitec Biopharma Ltd’s price range in the past 12 months?
Benitec Biopharma Ltd lowest stock price was €3.06 and its highest was €3.06 in the past 12 months.
What is Benitec Biopharma Ltd’s market cap?
Benitec Biopharma Ltd’s market cap is €369.75M.
When is Benitec Biopharma Ltd’s upcoming earnings report date?
Benitec Biopharma Ltd’s upcoming earnings report date is Sep 30, 2026 which is in 31 days.
How were Benitec Biopharma Ltd’s earnings last quarter?
Benitec Biopharma Ltd released its earnings results on May 14, 2026. The company reported -€0.207 earnings per share for the quarter, beating the consensus estimate of -€0.231 by €0.024.
Is Benitec Biopharma Ltd overvalued?
According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued.
Does Benitec Biopharma Ltd pay dividends?
Benitec Biopharma Ltd does not currently pay dividends.
What is Benitec Biopharma Ltd’s EPS estimate?
Benitec Biopharma Ltd’s EPS estimate is -0.23.
How many shares outstanding does Benitec Biopharma Ltd have?
Benitec Biopharma Ltd has 34,354,336 shares outstanding.
What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?
Benitec Biopharma Ltd reported an EPS of -€0.207 in its last earnings report, beating expectations of -€0.231. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Benitec Biopharma Ltd?
Currently, no hedge funds are holding shares in DE:BJ9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Benitec Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.73 (348.82% Upside)
€13.73 (348.82% Upside)
Blogger Sentiment
Bullish
DE:BJ9 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Benitec Biopharma Ltd
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
BJ9 Stock 12 Month Forecast
Average Price Target
€13.73
▲(348.82% Upside)
Technical Analysis
Tvardi Therapeutics
―
Assembly Biosciences
―
Rocket Pharmaceuticals
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―